More sophisticated tools such as circulating tumor DNA (ctDNA) analysis and radiomics-based imaging signatures have shown promise in early studies for predicting response to NAT and long-term outcomes [29,30], but neither has yet been validated in prospective, multicenter trials. This evidence concerns the gene BRD2 and neoplasm.